Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 5.20

From 52W high−22.64%

Volume23.94M

Market capCNY 5.38B

P/E (TTM)−39.9x

P/S (TTM)7.3x

Div yield—

Key dataSep 18, 2026

Open

CNY 5.20

From 52W high

−22.64%

Volume

23.94M

Market cap

CNY 5.38B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−50.2x

P/E (TTM)

−39.9x

RSI (14)

48.9

MomentumView details →

1D Return

−3.42%

YTD Return

+2.14%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−39.9x

EV/EBITDA

−50.2x

EV/Sales

6.5x

P/S (TTM)

7.3x

P/B (TTM)

3.1x

ProfitabilityView details →

Gross Margin

55.31%

Net Margin

−17.90%

EBITDA Margin

−12.86%

ROE (TTM)

−7.81%

ROA (TTM)

−5.20%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

−6.57%

EPS YoY

−40.47%

FCF YoY

+129.31%

Revenue CAGR 3Y

−4.28%

EPS CAGR 3Y

−53.37%

EBITDA YoY

—

MomentumView details →

1D Return

−3.42%

YTD Return

+2.14%

1Y Return

+18.78%

RSI (14)

48.9

vs 50D SMA

+1.13%

vs 200D SMA

−0.62%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

2.01x

Quick Ratio

1.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

759.50M

Net Income (TTM)

−135.94M

Op. CF (TTM)

34.79M

Latest newsMore news →

Chongqing Lummy Longyu Pharmaceutical, a wholly owned subsidiary of Lummy Pharmaceutical, received approval from China's National Medical Products Administration to produce and market finerenone as an active pharmaceutical ingredient in China.7d ago

Lemei Pharmaceutical obtained the Drug Registration Certificate for Acetylcysteine Solution for Inhalation (3ml:0.3g) approved by the National Medical Products Administration, valid until August 3, 2031, for the treatment of respiratory diseases.42d ago

Similar companies

山大电力301609.SZ 广哈通信300711.SZ 常友科技301557.SZ 深中华A000017.SZ 沃特股份002886.SZ 晨曦航空300581.SZ Find similar companies →

Latest newsMore news →

Chongqing Lummy Longyu Pharmaceutical, a wholly owned subsidiary of Lummy Pharmaceutical, received approval from China's National Medical Products Administration to produce and market finerenone as an active pharmaceutical ingredient in China.7d ago Lemei Pharmaceutical obtained the Drug Registration Certificate for Acetylcysteine Solution for Inhalation (3ml:0.3g) approved by the National Medical Products Administration, valid until August 3, 2031, for the treatment of respiratory diseases.42d ago